DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

Information source: Tokyo Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Macular Edema; Branch Retinal Vein Occlusion; Central Retinal Vein Occlusion

Intervention: ranibizumab (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Tokyo Medical University

Official(s) and/or principal investigator(s):
Hidetaka Noma, MD, Principal Investigator, Affiliation: Hachioji Medical Center, Tokyo Medical University

Overall contact:
Hidetaka Noma, MD, PhD, Phone: 81-42-665-5611, Ext: 7648, Email: noma-hide@umin.ac.jp

Summary

The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab by determining the pathogenesis of macular edema, which cause a direct effect on visual function. In particular, we focus on the correlation between the treatment effectiveness of ranibizumab and the role of the cytokines involved in the cause of macular edema.

Clinical Details

Official title: Study on the Correlation Between the Treatment Effectiveness of Ranibizumab and the Role of the Cytokines in Macular Edema With Retinal Vein Occlusion

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Visual function by ranibizumab in macular edema with retnal vein occlusion

Secondary outcome: Cytokine levels by ranibizumab in macular edema with retnal vein occlusion

Detailed description: Methodology: Aqueous humor samples (0. 1ml) were obtained during intravitreous injection of ranibizumab to measure the levels of cytokines. Targeted cytokines are follows; IL-1, IL-2, IL-6, IL-8, IL-9, IL-10, IL-12, IL-13, IP-10, MCP-1, MMP-1, MIP-1β, PDGF, VEGF, PlGF, ICAM-1, TNF-α, RANTES, VEGFR-1, VEGFR-2, which has been reported that the expression level is increased in macular edema associated with RVO. Cytokines are measured by multiple ELISA (Luminex). Aqueous humor samples are obtained in the same manner from patients recurred after the first injection or continuous monthly injections. Statistical analysis is conducted to examine the difference of cytokine levels between early or late/incomplete responders of ranibizumab, and predict the number of injections to stabilize cytokine levels. Number of centers & patients: Single center, 100 patients Sample size justification: Sample size calculation was not done, since this study is a single-arm, observational study. Population: Inclusion criteria: patients with RVO and macular edema

Eligibility

Minimum age: 30 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Foveal thickness > 300 μm

- Best corrected visual acuity < 20/30

Exclusion Criteria:

- History of retinal diseases other than BRVO, glaucoma, uveitis, diabetes mellitus,

rubeosis iridis, ocular infections, laser photocoagulation, and intraocular surgery

Locations and Contacts

Hidetaka Noma, MD, PhD, Phone: 81-42-665-5611, Ext: 7648, Email: noma-hide@umin.ac.jp

Hachioji Medical Center, Tokyo Medical University, Tokyo 193-0998, Japan; Recruiting
Hidetaka Noma, MD, PhD, Principal Investigator

Hachioji Medical Center, Tokyo Medical University, Tokyo 193-0998, Japan; Recruiting
Hidetaka Noma, MD, PhD, Phone: 81-42-665-5611, Ext: 7648, Email: noma-hide@umin.ac.jp
Hidetaka Noma, MD, PhD, Principal Investigator

Additional Information

Starting date: December 2013
Last updated: June 18, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017